Effect of GLP-1 Receptors Agonist Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

Trial Profile

Effect of GLP-1 Receptors Agonist Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Lixisenatide (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Jan 2017 Status changed from completed to discontinued.
    • 26 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top